Celldex Therapeutics reported $-36004000 in Net Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 924M 3566M
Agenus AGEN:US $ -46.43M 1.89M
Amgen AMGN:US $ 1317M 159M
Applied Genetic Technologies AGTC:US $ -14.29M 4.85M
Biocept BIOC:US $ -2.77M 0.2M
Bristol Myers Squibb BMY:US $ 1421M 143M
Celldex Therapeutics CLDX:US $ -36M 12.95M
Cytrx CYTR:US -1295910 7.73M
Glaxosmithkline GSK:US $ 838M 964M
Immunogen IMGN:US $ -62.02M 37.88M
Merrimack Pharmaceuticals MACK:US $ -478000 346K
Nektar Therapeutics NKTR:US $ -159.07M 68.68M
Newlink Genetics NLNK:US $ -7.72M 2.08M
Northwest Biotherapeutics NWBO:US -14214000 147.53M
Pfizer PFE:US $ 9905M 2042M
Rigel Pharmaceuticals RIGL:US $ -13.49M 13.95M
Seattle Genetics SGEN:US $ -134.83M 1.67M